Auxilius Pharma

Auxilius Pharma is a private, pre-revenue biotech targeting high unmet needs in chronic stable angina through its lead program, AUX-001, a once-daily formulation of nicorandil. The company's strategy centers on the 'Value-Added Medicines' paradigm, optimizing established drugs with proven safety and efficacy to create new formulations with improved convenience and clinical benefits, such as reduced hospitalizations. Led by CEO Jed Litwiniuk and supported by a seasoned team and scientific advisory board, Auxilius is positioning its lead candidate as a potential first-line treatment with a unique value proposition for payors due to its risk-reduction profile. The company is currently in Phase 1 development for its sole disclosed asset.

Value-Added Medicines (VAM) model focused on optimizing established drugs through improved formulations (e.g., once-daily dosing) and leveraging known secondary benefits to address unmet needs and create new IP.

Competes in the crowded chronic angina market dominated by generic beta-blockers, calcium channel blockers, and nitrates, as well as branded ranolazine. Differentiation is based on unique mechanism, safety in bradycardia, once-daily dosing, and claimed hospitalization benefit, not head-to-head efficacy against generics.